MLAB
Mesa Laboratories, Inc. · Healthcare · Medical - Specialties
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 3.62K | $456,842 | n/a | n/a |
| Q2 2026 | 67 | 0 | 2.99M | $297.50M | +4 | −4 |
| Q1 2026 | 70 | 0 | 2.66M | $235.21M | +6 | −6 |
| Q4 2025 | 70 | +2 | 2.73M | $214.06M | +2 | n/a |
| Q3 2025 | 17 | +1 | 1.54M | $103.48M | +2 | −1 |
| Q2 2025 | 13 | +4 | 1.73M | $163.31M | +4 | n/a |
| Q1 2025 | 6 | -3 | 383.09K | $45.46M | n/a | −3 |
| Q4 2024 | 9 | +1 | 400.64K | $52.84M | +1 | n/a |
| Q3 2024 | 7 | 0 | 174.94K | $22.72M | +1 | −1 |
| Q2 2024 | 7 | n/a | 189.52K | $16.45M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 3.62K | -15.2% | $456,842 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 158 holders, 4.82M shares, $424.86M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer · President and CEO · 7.09K sh @ 112.80 · $800,090
Director · 900 sh @ 113.69 · $102,321
Open-market sales (S)
Director · 7.09K sh · $800,090
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology